Quick Answer
Entera Bio Ltd. reported Net Income Loss of -$11.44 million for the year ending 2025.
- Entera Bio Ltd. showed a decrease of -19.9% in Net Income Loss from 2024 to 2025.
- This data is from Entera Bio Ltd.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$2.30 million | Q2 2021: -$2.58 million | Q3 2021: -$3.21 million | Q1 2022: -$3.78 million | Q2 2022: -$3.19 million | Q3 2022: -$3.07 million | Q1 2023: -$2.19 million | Q2 2023: -$2.33 million | Q3 2023: -$2.38 million | Q1 2024: -$2.02 million | Q2 2024: -$2.15 million | Q3 2024: -$3.02 million | Q1 2025: -$2.57 million | Q2 2025: -$2.66 million | Q3 2025: -$3.20 million.
- Over the full 6 years of available data (2020 to 2025), Entera Bio Ltd.'s Net Income Loss has declined by 2.0%.
- Historical annual values: Fiscal year 2025: -$11.44 million | Fiscal year 2024: -$9.54 million | Fiscal year 2023: -$8.89 million | Fiscal year 2022: -$13.07 million | Fiscal year 2021: -$12.19 million | Fiscal year 2020: -$11.22 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: